AVR 7.24% $11.27 anteris technologies ltd

Does the vax deal matter?, page-4

  1. 2,419 Posts.
    lightbulb Created with Sketch. 390
    Agree 100% on your first point.

    Agree partly on your second point; that any potential Vax deal definitely to be funded,100%, by 3rd party, upfront funds to Admedus a ‘super’ outcome, percentage of future royalties (likely to be limited) almost a ‘given’ as part of the deal.

    That a ‘ ... bounty from products which might eventuate from AI products ... ‘ is a reality that it that far in the future that it has no relevance, sorry to say that.

    Future of Admedus should be 100% solely focused, imo, on the Adapt IP, this will possibly, in years to come, be a company that is vastly different from the ‘beast’ it was pre Code Red era.

    This is pretty corny but imagine this company transforming from a larvae to a caterpillar to a butterfly .... lol, make note to myself, don’t drink Wild Turkey and post!
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.